Andreev T, Rashkov R
Vutr Boles. 1988;27(6):63-6.
146 patients with systemic lupus erythematodes were followed up. The patients are classified into two groups: I group--includes 74 patients treated during the 1953-1980. II group--of 72 patients treated during the period 1980-1987. Of the 74 patients of the I group 38 (51%) are still alive and 38 patients (49%) have died. From the II group 67 (93%) are alive and only 5 patients (7%) have died. 56% of the deceased patients died during the first 5 years. The following 5 years the death rate is twice as small--II dead patients (27%). Only 3 patients survived more than 15 years. The leading causes of death are: lupus nephropathy--18 patients (44%), cardiovascular lesions--12 patients (30%), neurologic complications and lately--infectious complications. A correlation between age and evolution of the disease is found: in younger age the evolution is more rapid. The analysis of the treatment of the patients from the II group reveals that the longer survival is due to the correct application of antimalarial drugs, cortisone drugs, imuran, pylse therapy with cortisone or a combination of these drugs.
对146例系统性红斑狼疮患者进行了随访。患者分为两组：第一组——包括1953年至1980年期间接受治疗的74例患者。第二组——72例患者于1980年至1987年期间接受治疗。第一组的74例患者中，38例（51%）仍存活，38例（49%）已死亡。第二组中，67例（93%）存活，仅5例（7%）死亡。56%的死亡患者在最初5年内死亡。接下来的5年，死亡率降低一半——27%的患者死亡。只有3例患者存活超过15年。主要死亡原因是：狼疮性肾病——18例（44%），心血管病变——12例（30%），神经并发症以及近期的感染并发症。发现年龄与疾病进展之间存在相关性：年龄较小者疾病进展更快。对第二组患者治疗情况的分析表明，更长的生存期归因于抗疟药物、皮质类固醇药物、硫唑嘌呤的正确应用，皮质类固醇脉冲疗法或这些药物的联合应用。
